Does the likelihood of having a BRCA gene mutation differ among populations? Who should consider genetic counseling and testing for inherited harmful changes in BRCA1 and BRCA2 ? How is genetic testing for harmful changes in BRCA1 and BRCA2 done?

Evidence-based, expert-reviewed summary about the BRCA1 and BRCA2 genes and hereditary breast and ovarian cancer. This summary also contains information about the cancer risks associated with BRCA1/BRCA2, screening, risk-reduction, treatment, and prognosis.

Hoja informativa sobre los genes BRCA1 y BRCA2, qué hacer si la prueba de una persona indica que tiene cambios en uno de estos genes y las consecuencias de las pruebas genéticas.

NCI-funded research helped identify inherited BRCA1 and BRCA2 genetic mutations and their connection to breast and ovarian cancer. From this research, a screening test was also developed to help patients make informed decisions about their health.

Apr 15, 2024 · Those with harmful BRCA1 or BRCA2 changes who had the surgery, the study found, had a lower risk of dying from ovarian cancer and breast cancer than those who didn’t. Results from both studies were published February 29 in JAMA Oncology.

Gen que da origen a una proteína que repara el ADN dañado. Las mutaciones (cambios) en el gen BRCA1 aumentan mucho el riesgo de presentar cáncer de mama y cáncer de ovario.

Jan 29, 2018 · The Food and Drug Administration has approved olaparib (Lynparza®) to treat metastatic breast cancers that have inherited mutations in the BRCA1 or BRCA2 genes as well as a companion diagnostic test for selecting candidates for the therapy.

Jun 26, 2019 · Olaparib (Lynparza) may benefit some people with advanced pancreatic cancer who have BRCA1 or BRCA2 mutations, according to the POLO trial results.

Jul 12, 2017 · Women who know they have inherited a harmful BRCA1 or BRCA2 mutation can take steps to reduce their risk of breast and ovarian cancer. But any preventive measures—including intensive early surveillance , use of chemoprevention , and prophylactic surgery —come with their own risks.

Long before scientists completed mapping the human genome in 2003, geneticist Mary-Claire King discovered BRCA1, the first gene for a hereditary form of breast cancer. That feat in 1990 helped explain why some women who carried mutations in this gene saw their lifetime risk for developing breast cancer rise from 8% to over 80%.